As of 11 August 2026, the Health Technology Assessment (HTA) Council has completed the evidence appraisal on the assessment of trastuzumab 440 mg lyophilized powder for intravenous (IV) infusion for the treatment of HER-2 overexpressing early-stage breast cancer, taken alone or in combination with chemotherapy. The HTA Council hereby releases its preliminary recommendation on the said health technology for stakeholder feedback and comments from 11 to 24 August 2026.

As a preliminary recommendation, the HTA Council recommends the government financing of trastuzumab 440 mg lyophilized powder for intravenous (IV) infusion. For the supporting evidence reviewed and discussed by the HTA Council, please refer to the document below.

All comments, inputs, and/or appeals on the above preliminary recommendation may be submitted until 24 August 2026 (Monday), for the consideration of the HTA Council, through email at hta@dost.gov.ph. Please use the prescribed form for appeals indicated in the official HTA Philippines website [https://hta.dost.gov.ph/appeals-2/]. Appeals not following the prescribed format and those submitted beyond the deadline shall not be entertained.